Differential regulation of metzincins in experimental chronic renal allograft rejection: Potential markers and novel therapeutic targets

Kidney International

Volumn 69, Issue 2, 2006, Pages 358-368

  Berthier, C C ^a,b   Lods, N ^a   Joosten, S A ^c   Van Kooten, C ^c   Leppert, D ^d   Lindberg, R L P ^d   Kappeler, A ^a   Raulf, F ^e   Sterchi, E E ^a   Lottaz, D ^a   Marti, H P ^a,f  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BASEL   (Switzerland)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chronic rejection; Matrix metalloproteinases; Meprin; Metzincins; Renal allograft; Tissue inhibitors of metalloproteinases

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14; MEPRIN; MESSENGER RNA; METZINCIN; PARAFFIN; PROTEIN SUBUNIT; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC GRAFT REJECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; FROZEN SECTION; HEALTH STATUS; IMMUNOHISTOLOGY; KIDNEY ALLOGRAFT REJECTION; KIDNEY HOMOGENATE; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; RAT STRAIN; REGULATORY MECHANISM; STAINING; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; ZYMOGRAPHY;

ADAM PROTEINS; ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED F344; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HOMOLOGOUS;

EID: 33644657040     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000049     Document Type: Article

References (57)

1. Cardarelli F, Saidman S, Theruvath T et al. The problem of late allograft loss in kidney transplantation. Minerva Urol Nefrol 2003; 55: 1-11.
2. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
3. Lovett DH, Johnson RJ, Marti HP et al. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 1992; 141: 85-98.
4. Turck J, Pollock AS, Lee LK et al. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271: 15074-15083.
5. Carmago S, Shah SV, Walker PD. Meprin, a brush-border enzyme, plays an important role in hypoxic/ischemic acute renal tubular injury in rats. Kidney Int 2002; 61: 959-966.
6. Norman LP, Jiang W, Han X et al. Targeted disruption of the meprin beta gene in mice leads to underrepresentation of knockout mice and changes in renal gene expression profiles. Mol Cell Biol 2003; 23: 1221-1230.
7. Bertenshaw GP, Norcum MT, Bond JS. Structure of homo- and heterooligomeric meprin metalloproteinases. J Biol Chem 2003; 278: 2522-2532.
8. Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999; 878: 442-452.
9. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM. The ADAM family of proteins: from basic studies to potential clinical applications. Thromb Haemost 2003; 89: 622-631.
10. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-735.
11. Cuvelier A, Kuntz C, Sesboue R et al. Les metalloproteinases de la matrice extracellulaire (MMP): structure et activité. Rev Mal Resp 1997; 14: 1-10.
12. Laplante A, Liu D, Demeule M et al. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection. Transpl Int 2003; 16: 262-269.
13. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992; 288: 93-99.
14. Kitamura M, Shirasawa T, Maruyama N. Gene transfer of metalloproteinase transin induces aberrant behavior of cultured mesangial cells. Kidney Int 1994; 45: 1580-1586.
15. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
16. Conway JG, Wakefield JA, Brown RH et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995; 182: 449-457.
17. Gijbels K, Galdary RE, Steinmann L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994; 94: 2177-2182.
18. Lelongt B, Trugnan G, Murphy G, Ronco PM. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol 1997; 136: 1363-1373.
19. Hill PA, Docherty JP, Bottomley KM et al. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J 1995; 308: 167-175.
20. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 2001; 36: 249-257.
21. Sanceau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003; 278: 36537-36546.
22. Villa JP, Bertenshaw GP, Bond JS. Critical amino acids in the active site of meprin metalloproteinases for substrate and peptide bond specificity. J Biol Chem 2003; 278: 42545-42550.
23. Kruse MN, Becker C, Lottaz D et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J 2004; 378: 383-389.
24. Sterchi EE, Naim HY, Lentze MJ. Biosynthesis of N-benzoyl-L-tyrosyl-p- aminobenzoic acid hydrolase: disulfide-linked dinners are formed at the site of synthesis in the rough endoplasmic reticulum. Arch Biochem Biophys 1988; 265: 119-127.
25. Kohler D, Kruse M, Stocker W, Sterchi EE. Heterologously overexpressed, affinity-purified human meprin α is functionally active and cleaves components of the basement membrane in vitro. FEBS Lett 2000; 465: 2-7.
26. Kieran NE, Doran PP, Connolly SB et al. Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 2003; 64: 480-492.
27. Trachtman H, Valderrama E, Dietrich JM, Bond JS. The role of meprin A in the pathogenesis of acute renal failure. Biochem Biophys Res Commun 1995; 208: 498-505.
28. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 2002; 11: 1003-1006.
29. Joosten SA, van Dixhoorn MGA, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310.
30. Joosten SA, van Ham V, Nolan CE et al. Telomere shortening and cellular senescence in a model of chronic renal allograft rejection. Am J Pathol 2003; 162: 1305-1312.
31. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
32. Marti HP, McNeil L, Thomas G et al. Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J 1992; 285: 899-905.
33. Inaki N, Tsunezuka Y, Kawakami K et al. Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas. J Heart Lung Transplant 2004; 23: 218-227.
34. Hernandez-Barrantes S, Toth M, Bernardo MM et al. Binding of active (57 kDa) membrane type-1 matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 2000; 275: 12080-12089.
35. Lods N, Ferrari P, Frey FJ et al. Angiotensin converting enzyme inhibition but not angiotensin II receptor blockade reduces matrix metalloproteinase activity in glomerulonephritis. J Am Soc Nephrol 2003; 14: 2861-2872.
36. Lorenzl S, Albers DS, Relkin N et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003; 43: 191-196.
37. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-10432.
38. Eberhardt W, Beeg T, Beck KF et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000; 57: 59-69.
39. Takei I, Takagi M, Santavirta S et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints. J Biomed Mater Res 1999; 45: 175-183.
40. Yang YN, Bauer D, Wasmuth S et al. Matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) during the course of experimental necrotizing herpetic keratitis. Exp Eye Res 2003; 77: 227-237.
41. Lu KV, Jong KA, Rajasekaran AK et al. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004; 84: 8-20.
42. Kaushal GP, Walker PD, Shah SV. An old enzyme with a new function: purification and characterization of a distinct matrix-degrading metalloproteinase in rat kidney cortex and its identification as meprin. J Cell Biol 1994; 126: 1319-1327.
43. Johnson GD, Hersh LB. Expression of meprin subunit precursors. Membrane anchoring through the beta subunit and mechanism of zymogen activation. J Biol Chem 1994; 269: 7682-7688.
44. Rodrigo E, López Hoyos M, Escallada R et al. Changes in serum concentrations of matrix metalloproteinases in kidney transplantation. Transplant Proc 2000; 32: 517-518.
45. Rodrigo E, López-Hoyos M, Escallada R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant patients with chronic transplant nephropathy. Nephrol Dial Transplant 2000; 15: 2041-2045.
46. Ermolli M, Schumacher M, Lods N et al. Differential expression of MMP-2/MMP-9 and potential benefit of MMP inhibitor in experimental acute kidney allograft rejection. Transplant Immunol 2003; 11: 137-145.
47. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75: 772-780.
48. Warner RL, Lewis CS, Beltran L et al. The role of metalloelastase in immune complex-induced acute lung injury. Am J Pathol 2001; 158: 2139-2144.
49. Bax DV, Messent AJ, Tart J et al. Integrin alpha 5beta 1 and TNF-α converting enzyme (TACE/ADAM-17) interact in vitro and colocalise in migrating HeLa cells. J Biol Chem 2004 [E-pub ahead of print].
50. Rosmann S, Hahn D, Lottaz D et al. Activation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen- activating system. J Biol Chem 2002; 277: 40650-40658.
51. Ramont L, Pasco S, Hornebeck W et al. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp Cell Res 2003; 291: 1-10.
52. Steinmann-Niggli K, Küng M, Ziswiler R, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 1998; 9: 397-407.
53. Steinmann-Niggli K, Lukes M, Marti HP. Rat mesangial cells and matrix metalloproteinase inhibitor: Inhibition of 72-kDa type IV collagenase (MMP-2) and of cell proliferation. J Am Soc Nephrol 1997; 8: 395-405.
54. Daniel C, Duffield J, Brunner T et al. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther 2001; 297: 57-68.
55. Szabo A, Lutz J, Schleimer K et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991.
56. Leib SL, Clements JM, Lindberg RL et al. Inhibition of matrix metalloproteinases and tumour necrosis factor α converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001; 124: 1734-1742.
57. Lottaz D, Hahn D, Müller S et al. Secretion of human meprin from intestinal epithelial cells depends on differential expression of the α and β subunits. Eur J Biochem 1999; 259: 496-504.